SG/CALL/NOVO-NORDISK B/750/0.1/20.12.24 | Market Closed - Boerse Frankfurt Warrants 03:43:35 2024-07-16 pm EDT | ||
| 3.17 EUR | -0.94% |
|
| Current month | -10.70% | ||
| 1 month | -9.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 3.17 | -0.94% |
| 24-07-15 | 3.2 | -2.74% |
| 24-07-12 | 3.29 | +6.13% |
| 24-07-11 | 3.1 | -6.91% |
| 24-07-10 | 3.33 | +3.42% |
Real-time Boerse Frankfurt Warrants
Last update July 16, 2024 at 03:43 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU5232 |
| ISIN | DE000SU52321 |
| Date issued | 2023-12-20 |
| Strike | 750 kr |
| Maturity | 2024-12-20 (157 Days) |
| Parity | 10 : 1 |
| Emission price | 1.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.94 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.08 € |
| Spread % | 2.46% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
